Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: The bone morphogenetic protein (BMP) is a critical signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others. Areas covered: This review covers small molecule inhibitors/antagonists of BMP in patent applications between 2008 – 2015, along with brief synopses of the disclosed inhibitors in the primary literature. Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile. Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP). Recently, however, there has been increased interest in their use in a number of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few. Although the primary participants in the early work were from academic laboratories, recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications. Due to this, expect a number of new approaches such as repurposing of other kinase inhibitors to be brought into clinical trials in the near future.

Original languageEnglish (US)
Pages (from-to)1115-1128
Number of pages14
JournalExpert Opinion on Therapeutic Patents
Volume26
Issue number10
DOIs
StatePublished - Oct 2 2016

Fingerprint

Bone Morphogenetic Proteins
Anemia
Atherosclerosis
Body Patterning
Myositis Ossificans
Neglected Diseases
Critical Pathways
Drug Industry
Expert Testimony
Skin Neoplasms
Rare Diseases
Skin Diseases
Osteogenesis
Names
Chronic Disease
Phosphotransferases
Pharmacokinetics
Clinical Trials
Neoplasms
Therapeutics

Keywords

  • ALK
  • BMP
  • Bone morphogenetic protein
  • activin receptor-like kinase
  • inhibitors
  • small molecule

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Inhibitors of the bone morphogenetic protein (BMP) signaling pathway : a patent review (2008-2015). / Hopkins, Corey R.

In: Expert Opinion on Therapeutic Patents, Vol. 26, No. 10, 02.10.2016, p. 1115-1128.

Research output: Contribution to journalReview article

@article{0db92149e7dc48bea96022f611eb5041,
title = "Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015)",
abstract = "Introduction: The bone morphogenetic protein (BMP) is a critical signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others. Areas covered: This review covers small molecule inhibitors/antagonists of BMP in patent applications between 2008 – 2015, along with brief synopses of the disclosed inhibitors in the primary literature. Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile. Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP). Recently, however, there has been increased interest in their use in a number of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few. Although the primary participants in the early work were from academic laboratories, recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications. Due to this, expect a number of new approaches such as repurposing of other kinase inhibitors to be brought into clinical trials in the near future.",
keywords = "ALK, BMP, Bone morphogenetic protein, activin receptor-like kinase, inhibitors, small molecule",
author = "Hopkins, {Corey R}",
year = "2016",
month = "10",
day = "2",
doi = "10.1080/13543776.2016.1217330",
language = "English (US)",
volume = "26",
pages = "1115--1128",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Inhibitors of the bone morphogenetic protein (BMP) signaling pathway

T2 - a patent review (2008-2015)

AU - Hopkins, Corey R

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Introduction: The bone morphogenetic protein (BMP) is a critical signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others. Areas covered: This review covers small molecule inhibitors/antagonists of BMP in patent applications between 2008 – 2015, along with brief synopses of the disclosed inhibitors in the primary literature. Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile. Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP). Recently, however, there has been increased interest in their use in a number of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few. Although the primary participants in the early work were from academic laboratories, recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications. Due to this, expect a number of new approaches such as repurposing of other kinase inhibitors to be brought into clinical trials in the near future.

AB - Introduction: The bone morphogenetic protein (BMP) is a critical signaling pathway and plays a diverse role in embryonic pattern formation and is implicated in a variety of disease processes, including anemia, bone formation, atherosclerosis, skin diseases, and cancers, among others. Areas covered: This review covers small molecule inhibitors/antagonists of BMP in patent applications between 2008 – 2015, along with brief synopses of the disclosed inhibitors in the primary literature. Expert opinion: The development of potent and selective BMP inhibitors is ongoing with most of the work centered around improving the selectivity and pharmacokinetic profile. Early work was for the treatment of the rare and neglected disease, fibrodysplasia ossificans progressiva (FOP). Recently, however, there has been increased interest in their use in a number of other diseases such as cancer, atherosclerosis, and anemia of chronic disease, to name a few. Although the primary participants in the early work were from academic laboratories, recently a significant surge from the pharmaceutical industry has elevated the interest in the development of BMP inhibitors for a wide-range of therapeutic indications. Due to this, expect a number of new approaches such as repurposing of other kinase inhibitors to be brought into clinical trials in the near future.

KW - ALK

KW - BMP

KW - Bone morphogenetic protein

KW - activin receptor-like kinase

KW - inhibitors

KW - small molecule

UR - http://www.scopus.com/inward/record.url?scp=84988661415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988661415&partnerID=8YFLogxK

U2 - 10.1080/13543776.2016.1217330

DO - 10.1080/13543776.2016.1217330

M3 - Review article

C2 - 27476794

AN - SCOPUS:84988661415

VL - 26

SP - 1115

EP - 1128

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 10

ER -